Patients with AD exhibit a straight-line relationship between the number of ERα and cognitive function, which further supports the idea of ‘ERα degradation’ and a less-than-optimal response to hormone therapy, no response, or even negative outcomes when initiated after a certain period [49]. The gene discussed is ESR1; the disease is Alzheimer disease.